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Abstract
Background: Common variable immunodeficiency (CVID) comprises a heterogeneous group of
primary antibody deficiencies with complex clinical and immunological phenotypes. The recent
discovery that some CVID patients show monogenic defects in the genes encoding ICOS, TACI or
CD19 prompted us to investigate several functional candidate genes in individuals with CVID.
Results: The exonic, protein coding regions of the genes encoding: APRIL, BCMA, IL10, IL10Rα,
IL10Rβ, IL21, IL21R, and CCL18, were analyzed primarily in familial CVID cases, who showed
evidence of genetic linkage to the respective candidate gene loci and CVID families with a recessive
pattern of inheritance. Two novel SNPs were identified in exon 5 and exon 8 of the IL21R gene,
which segregated with the disease phenotype in one CVID family. Eleven additional SNPs in the
genes encoding BCMA, APRIL, IL10, IL10Rα, IL21 and IL21R were observed at similar frequencies
as in healthy donors.
Conclusion: We were unable to identify obvious disease causing mutations in the protein coding
regions of the analyzed genes in the studied cohort.
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Background
Common variable immunodeficiency (CVID) is the most
prevalent symptomatic primary immunodeficiency in
adults. CVID clinically presents with a history of recurrent
infections at mucous membranes which is the conse-
quence of a marked hypogammaglobulinemia [1]. The
clinical course of CVID is complicated by a plethora of
systemic immunopathology including autoimmunity,
lymphoproliferation, malignancy and sarcoid-like granu-
lomas.
CVID affects males and females equally and usually man-
ifests in the second or third decade of life. A second peak
of onset exists in childhood between the ages of 2 and 5
years [2,3]. The prevalence of CVID in the Western hemi-
sphere is estimated to be approximately 1: 25.000 [1,4].
The majority of CVID cases are sporadic, while approxi-
mately 10 to 20% of CVID cases show at least one addi-
tional family member affected either by CVID or selective
IgA deficiency (sIgAD) [5,6]. Most multiplex CVID fami-
lies show an autosomal dominant mode of inheritance
but about 20% present with a recessive trait. CVID and
sIgAD deficiency may concur in a single kindred and
sIgAD may show progression to CVID in some affected
individuals over time [6-8].
Early association and more recent genetic linkage studies
have revealed several putative susceptibility loci for CVID/
sIgAD. While most of these studies combined families
with sIgAD and CVID, Vořechovský et al analyzed sIgA-
deficient families separately and identified a susceptibility
locus within the HLA region on chromosome 6p termed
"IGAD1" [9]. In 2003, the same group reported that cer-
tain HLA-DQ/DR haplotypes and not other putative can-
didate genes within the IGAD1  region confer the
protection from or susceptibility to sIgAD and CVID [10].
The same study suggested that the best prospects for non-
MHC susceptibility loci could be found on chromosomes
4p, 12p and 14q, but none of these three loci reached sta-
tistical significance.
We were recently able to demonstrate genetic linkage to
chromosome 16q for autosomal dominant CVID in this
cohort of families [9,10] by reanalysis of existing data
restricted to the families with at least one case of CVID, in
combination with additional fine-mapping [11]. Further-
more, genome-wide linkage analysis in a large multiplex
CVID family revealed linkage to a locus on chromosomes
4q. This locus on 4q was replicated (requiring a lower
standard of evidence than initial linkage) in a large cohort
of small families [12].
Thus, there is considerable genetic heterogeneity in CVID,
which mirrors the variable clinical presentation of the dis-
ease. Despite these conundrums, the discovery of genetic
defects in ICOS [13,14], TACI/TNFRSF13B [15,16] and
CD19 [17] provides proof that defects in single genes are
associated with a CVID phenotype and underscores the
value of candidate gene approaches in CVID. Further-
more, a considerable number of patients carrying muta-
tions in the above mentioned genes were derived from
familial cases showing recessive patterns of inheritance
and sometimes involving consanguinity. The only CVID
gene for which heterozygous mutations have been found
in sporadic patients is TACI/TNFRSF13B [15,18].
We therefore, focused in our candidate gene approach pri-
marily on familial CVID cases and multiplex CVID/sIgAD
families, which showed evidence for genetic linkage to the
respective candidate gene loci based on available geno-
type data [9,10]. We concentrated on cytokine/receptor
pairs, which showed involvement in terminal B cell differ-
entiation, preferential expression in germinal centers and
involvement in class switch recombination. More impor-
tantly, the available knockout mouse models of the stud-
ied genes present with phenotypes that partially resemble
aspects of human common variable immunodeficiency. A
flow chart summarizing the study design and selection cri-
teria for patients and candidate genes is provided in Figure
1.
In BCMA/TNFRSF17-deficient mice, the generation of
long lived plasma cells in the bone marrow is severely
impaired [19], which mirrors pathology observed in indi-
viduals with CVID [20]. APRIL/TNFSF13 is an important
factor that drives both human and murine B cells to
induce Ig heavy chain class switch to IgA and IgG [21].
Moreover, TNFSF13-deficient mice show a selective defi-
ciency in IgA [22].
Interleukin 10 (IL10) is an important immunoregulatory
cytokine, which supports terminal B cell differentiation
and has potent anti-inflammatory effects. Furthermore,
IL10 production by T cells is deficient in human ICOS
deficiency [14], X-linked lymphoproliferative disease [23]
and in subsets of CVID patients [24], further underscoring
the potential involvement of IL10 in the pathogenesis of
hypogammaglobulinemia. Finally, IL10-deficient mice
develop inflammatory bowel disease, a condition remi-
niscent of what can be observed in patients with CVID [3].
Signaling via IL21 and the IL21 receptor can induce apop-
tosis in B cells [25]. However, the interaction is also cru-
cial for terminal B cell differentiation [26,27]. The ability
of IL21 to drive plasma cell differentiation makes this
gene an attractive candidate gene for human CVID.
Chemokine (C-C motif) ligand 18 (CCL18) is a potent
chemoattractant for T cells and B cells, highly expressed inBMC Immunology 2008, 9:3 http://www.biomedcentral.com/1471-2172/9/3
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germinal centers of secondary lymphoid organs by den-
dritic cells [28].
Results
The genetic localization of the investigated genes, the
number of exons, the genotyping markers and the families
which were analyzed are summarized in Table 1. The ped-
igrees of all families analyzed in this study are shown in
Figure 2. Primers used for amplification and sequencing
are listed in Table 2.
Table 3 summarizes the observed sequence variations, the
in silico analysis of missense mutations by SIFT [29] and
Polyphen [30] and the genotype frequencies in the stud-
ied CVID cohort compared to healthy donors.
BCMA/TNFRSF17 and APRIL/TNFSF13
Seventeen probands of CVID families were analyzed.
Seven of these families were selected due to being linkage-
positive at the TNFRSF17  locus on chromosome 16p
(Table 1). In addition, we expanded our mutation screen-
ing in BCMA/TNFRSF17 to a larger cohort of 50 sporadic
CVID cases. One previously described heterozygous single
nucleotide polymorphism (SNP) was found in a proband
of family cv22 in exon 2: Ser81Asp [dbSNP: rs373496]. In
exon 3 two synonymous SNPs [dbSNP: rs2017662 and
rs2071336] were found in homozygous state in five indi-
viduals (family fr24 and four sporadic cases) and in heter-
ozygous state in probands of families cv73 and fr21. RT-
PCR was performed but evidenced no alternative splicing
products (data not shown). A novel variant was identified
in exon 3: K179Q, which was present in one individual.
The K179Q variant was present in the heterozygous state
both in affected and healthy members of the family,
which renders unlikely a contribution of this mutation to
the pathogenesis of the hypogammaglobulinemia. Flow
cytometric analysis confirmed normal expression of the
protein (data not shown).
APRIL/TNFSF13 was analyzed in the probands from 12
CVID families. The families cv73, cv97 and cv137 were
linkage positive at the TNFSF13 locus (Table 1). Two pre-
viously described non-synonymous SNPs [dbSNP:
rs11552708 and rs3803800], located in exon 1 and exon
2 respectively, were found in the studied cohort (Table 3).
IL10, IL10 receptor α and IL10 receptor β
The IL10 gene was sequenced in 23 individuals. Of those,
13 represented autosomal recessive CVID families, five
families were selected for being linkage-positive, and five
were sporadic CVID cases showing a clinical phenotype
compatible with inflammatory bowel disease (Table 1). 
Selection of patients and candidate genes Figure 1
Selection of patients and candidate genes.
genetic mouse models in vitro immunological studies known gene defects in CVID
candidate gene selection
APRIL BCMA IL21
IL10
IL21R
IL10Rβ CCL18 IL10Rα
Selection of 
gene – patient pairs
to be sequenced
Clinical data on patients 
and relatives
genotype data 
on familial cases
gene – patient pairs in Table 1BMC Immunology 2008, 9:3 http://www.biomedcentral.com/1471-2172/9/3
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One previously described heterozygous SNP [rs3024496]
located in the 3'UTR of the IL10 gene was found in fre-
quencies comparable to that in healthy controls (Table 3).
IL10 receptor α, encoded by IL10RA was analyzed in 22
individuals, of whom 12 belonged to autosomal recessive
families, five were from linkage-positive families at the
IL10RA locus, and five were sporadic CVID cases (Table
1). The known synonymous SNP [dbSNP: rs2256111] in
exon 4 and the SNP [dbSNP: rs17121493] in exon 5
(I224V) were observed in frequencies comparable to
those which are reported for normal controls in public
databases (Table 3).
The IL10RB gene was analyzed in 14 CVID patients, 10
from CVID families (six of them linkage-positive at the
IL10RB locus) and four sporadic CVID cases (Table 1). We
found no genetic alterations in the 7 exons of IL10RB.
IL21 and IL21 receptor
The 5 exons of IL21 were amplified and sequenced in 25
individuals (19 autosomal recessive CVID (AR-CVID)
families and 6 autosomal dominant CVID families (AD
CVID) that are linkage-positive at the IL21 locus). In exon
3 of the IL21  gene the synonymous change [dbSNP:
rs4833837] was observed in a frequency comparable to
that reported in public databases (Table 3).
The IL21R gene was analyzed in 24 individuals (19 AR
CVID families and 5 AD CVID families linkage-positive at
the IL21R locus). In exon 1 of IL21R the SNP [dbSNP:
rs961914] was observed in homozygous state in the
proband from family fr18 and in heterozygous state in
cv32, fr25, fr28 and fr29. In exon 5 of the IL21R gene we
found a previously undescribed heterozygous SNP result-
ing in the replacement of a conserved threonine by
methionine at position 46 in the proband from family cv4
(Figure 3). In addition, a new heterozygous change in
exon 8 resulting in R275Q was found in the family cv72.
Both heterozygous substitutions showed perfect segrega-
tion with the disease phenotype in these families (Figure
3). However, we subsequently screened a cohort of 100
healthy individuals with normal immunoglobulin levels
and found respectively 2 (T46M) and 5 (R275Q) hetero-
zygous individuals among them, suggesting that these two
coding sequence changes may not be disease-associated.
CCL18
The three exons of CCL18 including the 5'and 3'untrans-
lated region were amplified and analyzed in 19 probands
including six from CVID families linkage-positive at the
CCL18 locus on chromosome 17 (Table 1). No genetic
alterations were found.
Discussion
In recent years, genetic linkage analysis of selective IgA
deficiency (sIgAD) and common variable immunodefi-
ciency (CVID) has led to the identification of several sus-
ceptibility loci [10-12]. However, all four molecular
genetic defects underlying CVID reported to date, namely
ICOS [13], TACI [15,16], CD19 [17] and BAFF-R [31]
were identified by a candidate gene approach using either
Table 1: Investigated candidate genes and analyzed families.
Gene Chromosomal 
location
Exons Markers used for 
genotyping
Linkage-positive CVID 
families for the 
respective locus
Autosomal recessive 
CVID families
# of sporadic CVID 
patients
BCMA/TNFRSF17 16p13.1 11.9 
Mb–12.0 Mb
3 D16S423, D16S407, 
D16S405
cv22, cv72, cv73, cv91, 
cv128, cv135, cv136
fr6, fr16, fr17, fr19, 
fr20, fr21, fr22, fr23, 
fr24, cv32
50
APRIL/TNFSF13 17p13.1 7.4 Mb 6 D17S513, D17S786 cv73, cv97, cv137 fr6, fr17, fr18, fr20, 
fr21, fr22, fr23, fr24, 
fr27
NA
IL10 1q31-q32 205 Mb 5 D1S1660, D1S1678, 
D1S1663, D1S2141, 
D1S229
cv73, cv77, cv125, 
cv128, cv136
fr6, fr16–fr26, fr28 5 (IBD)
IL10RA 11q23.3 117.3 
Mb–117.4 Mb
7 D11S927, D11S925, 
D11S934
cv18, cv53, cv72, cv75, 
cv136
fr6, fr16–fr23, fr25, 
fr26, cv32
5 (IBD)
IL10RB 21q22.11 33.5 
Mb–33.6 Mb
7 D21S265, D21S65, 
D21S219, D21S270, 
D21S167
cv4, cv22, cv32, cv75, 
cv80, cv128
fr6, fr16, fr17, fr18 4 (IBD)
IL21 4q26-q27 123.7 
Mb–123.8 Mb
5 D4S430, D4S427 cv4, cv52, cv53, cv59, 
cv74, cv135
fr6, fr16–fr26, 
fr28–fr33, cv32
NA
IL21R 16p11 27.3 Mb–27.4 
Mb
9 D16S420, D16S261, 
D16S411
cv4, cv22, cv72, cv77, 
cv137
fr6, fr16–fr26, 
fr28–fr33, cv32
NA
CCL18 17q11.2 31.4 Mb 3 D17S798, D17S250 cv18, cv78, cv80, cv93, 
cv125, cv136
fr6, fr16–fr26, fr28 NA
IBD, sporadic CVID patients with symptoms of inflammatory bowel disease; NA, not applicable.BMC Immunology 2008, 9:3 http://www.biomedcentral.com/1471-2172/9/3
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phenotypic or genetic screening of genes known to be
involved in B cell homeostasis, B cell activation or the T-
B cell interaction. In the case of TACI/TNFRSF13B, linkage
analysis was used to identify one small CVID family with
the same homozygous mutation in two individuals [15].
The success with four CVID candidate genes stimulated
researchers to evaluate additional candidate genes that
encode proteins in the pathways of ICOS, TACI, BAFF-R,
and CD19 signaling [32,33]. Here we report on the anal-
ysis of eight additional candidate genes in CVID, where no
mutation was identified.
The candidacy of the genes encoding BCMA and APRIL
was strong since their close relatives BAFF-R and TACI
have recently been shown to be mutated in CVID
[15,16,31]. Although both TNFRSF17 and TNFSF13 were
shown to be polymorphic in the studied cohort, none of
these changes were obviously disease related.
Table 2: Primer sequences for candidate genes.
Gene Exon Forward primer Reverse primer bp§ °C§
APRIL 1 CCTTGCTACCCCACTCTTGA TCTCTTGCACCCCCTTGAA 402 62
2 CTGGGAAAAGGTGCGTGAGA TGAGGAGAGAAGGAGGGAATC 337 62
3 AGCAGCGTGGGGATTGTAA CTCAGGTGCTTTTTGGTTCTTT 268 62
4 AAGTGGATGCGGCTGAGATT GGGAAGGGAGATGTTGAAGAA 536 62
5 CATACCAAACCCAGCAGAC GTTTCCAACCTCCCTCCTA 335 62
6 GCGGGTCTGAGGAGTGAAGT AGTCTAGGGGGTGGGAATGA 415 62
BCMA 1 GTCTATCTCCCTGGCACCTCTCAC CACTGCCTTGCTTCCTTTCTCTTT 685 55
2 CGGGAGGCTGAGGCAGGAG TCGAAAGGGCTGTAACGAAGTGAA 451 55
3 TCCCGACTGCTCTGTAGGCTAACG TTCTTTCCCCCTCCCACCTTTCTC 797 57
CCL18 1 ATCCCTGGGTGCTTCCAACTC TGCCCAGGGAGCCATCAA 414 57
2 CCAAGCGGTGATATCTCCCAGTTC AGGCCTTCCCCAAATGTCTCAGA 477 60
3a GAGGCCCCTGCAGTGTTTTGTG CTGGGCATAGCAGATGGGACTCTT 498 60
3b GCAGGGGCCACAGGATTCC TGCCCCTTTTCATATTTCCCTACT 680 57
IL10 1 GTGCCGGGAAACCTTGATTGTGG GGGGGAATAGGTGTTGGGGATGG 435 60
2 and 3 GGGCATCAAAAAGACCGCATTTCA CCCCCAACGCCTGCTCAAAGA 763 60
4 CCACCAGCTTGTCCCCTAAGTGTG TGGCCGGCCAGCCTAACC 404 59
5 AGCATGAGGGAGGGGAGCCTATTT GCGCCCGGCCTAGAACCAA 781 57
IL10RA 1 CGCTAGCGCCCCAGGACAG GTTTGCGGGTTGGGGGTTTG 545 64
2 ATGTGCCCACTCTGCCCCTTACG GGGCCCTCAGGCACTCACTTCATT 377 61
3 GGGCTGTCCCAGTTTCTCCCAATG CCCAACCCACCCCAAGACCTCTC 542 61
4 CAAAGTCTCGGCGGGGACACC CCTCCTCTGCCCACCCACCAT 388 61
5 AGGCCCACCAGCTCTCAGTGTCC CCAGGTGCACGCGTTTTGGATT 302 60
6 CTTGGGCCACTCACTGAATGGTT CCCACAGCGCTTGATGAAGGTAT 404 60
7 CCTTCCCCGGCAGCACTGG GCAGAGGAGCAGGCATGGCTAAAA 1048 63
IL10RB 1 GCGCCTTTCAAAGCTTGCGAGGAT GGCCGTGGCGTTTGCATCTTCTCT 442 65
2 ACCCACGTGGCCTTTGAAGACAT GTGGCCACGAGAATTTCCCAGAC 416 60
3 CCAGTCAGCCTCAGGGAGAC GGGCCCCAACATAGTCACAT 486 54
4 ACTTCCGTGGACTAATTGTTCTGC CTTCAGGGAGGGAAAGGTCTG 494 55
5 AGTCCCCCAAAGTGCTGTGATTAC GGGCGATAGATTTCTGAACTGAGC 575 57
6 TCTGAGACGTCCCCCAAGATAAAC TGGGCAGCCCTAACTAGAAAGGAA 359 57
7 CCAGCCAGGAGTTCTGTGAAAA TAGATGTGGGGCTGGCTCAGAT 382 57
IL21 1 and 2 AGTTACTCACATTCATCCAT CTGTCTCAGCAATACTACTT 736 50
3 GAAATAGAGGATTGGGAAAG GGTAAGGAAGACACCAGCAG 345 50
4 and 5 TACAAGGACTTTTTCCATTG GACTTTGCACACTTATGAGT 510 50
IL21R 1 TCTCTGCTGAGTGACCGTAAG TTCCTTCCCCAGCCCGCTACA 675 58
2 CAGCAAGGGCAAAATAGTCAG TGTCTACCGCTTCTGTTTCAT 898 57
3 TTGGGACATTTTCAGCATAGC ACCATTCATGGGAAGCGTGTA 863 59
4 TGCTGCCCTAAATGAGGTAGT AAAATTAGCTGGGTGTAGTGG 610 59
5 AGATGGGGTTTCACCGTGTTA TGCTCGTGCCCTTGGTCTCTG 699 55
6 TTGCTAAGATGTCTGTAGTTA GGGAAATGGGTCTGGGGTAGA 1067 55
7 CCCTGTTTTTCAGACGAGATA TTCAGAGGTGTGGACTATTAC 755 55
8 GTGAAGAGGTGGCTGTAATAG AGATGGGGAGGCGGAGTGGTG 768 55
9 AGTGAACCGAGATGGCACCAC AGGGAGGACGGCTGTTGTCAT 1270 59
IBD, sporadic CVID patients with symptoms of inflammatory bowel disease; NA, not applicable.BMC Immunology 2008, 9:3 http://www.biomedcentral.com/1471-2172/9/3
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The genes encoding IL10 and its receptor subunits were
selected as candidate genes for CVID, since we were able
to show that IL10 is the critical cytokine missing in ICOS
deficiency [16]. Furthermore, IL10 plays an important
role in B cell development. However, no mutations were
found in the investigated families.
In a context dependent manner IL21 is able to induce dif-
ferentiation of plasma cells and memory cells, or is able to
promote apoptosis of resting and anti-IgM-activated B
cells [25]. Ettinger et al recently showed that IL21 costim-
ulation in humans is capable of inducing substantial B-
cell expansion, plasma cell differentiation from CD27+
memory B-cells and class switch recombination [27].
Therefore, we screened multiple families for mutations in
IL21  and/or  IL21R. Apart from known SNPs we could
identify two new heterozygous variations in IL21R that
result in amino acid changes and segregated with the dis-
ease phenotype in families. However these changes were
also found in a screening of healthy individuals. This sug-
gests that these two variations may not be disease associ-
ated.
Conclusion
In summary, we cannot provide evidence that the above
listed eight genes are implicated in the etiology of CVID in
this studied cohort of patients. However, only protein
coding regions of the respective genes were analyzed leav-
ing the possibility of mutations in promoter or regulatory
regions. Based on other studies of humans and mice these
genes remain attractive candidate genes for CVID. Larger
CVID cohorts or cohorts of non-European origin may
enable the identification of rare mutations in these genes.
Methods
Notation convention used throughout this paper
For several of the genes we mention, such as TACI/
TNFRSF13B, the HUGO-approved gene acronym
(TNFRSF13B) has no resemblance to the protein acronym
Pedigrees of CVID families Figure 2
Pedigrees of CVID families. Left column: pedigrees of analyzed autosomal recessive CVID families; right column: pedigrees 
of selected CVID families based on positional reasoning with respect to candidate loci; symbols: circles, female; squares, male; 
filled symbols, affected individual; slash, deceased.
cv53 cv52
„linked“ CVID families
cv18 cv22
cv72
cv75
cv4
cv73
cv78
cv59 cv74
cv80 cv93 cv125 cv128
cv135 cv136 cv137
cv77
fr6 fr16 fr17
fr18 fr19 fr20
fr21 fr22 fr23
fr24 fr25 fr26 fr28
fr30 fr31 fr32 fr33 cv32
fr29 cv97
Autosomal recessive CVID familiesBMC Immunology 2008, 9:3 http://www.biomedcentral.com/1471-2172/9/3
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(TACI), which is much more familiar to immunologists.
In those cases, we use either the protein name alone or the
compound notation protein/gene, when referring to either
the gene or the protein it encodes.
Patients and families
Twenty families with at least one case of CVID were
selected from a collection of 101 multiplex CVID/IgA defi-
cient families [5,9,10,34], based in part on reanalysis of
genotype data previously generated for genetic linkage
studies. This method had successfully identified family A
as consistent with linkage to the TACI/TNFRSF13B locus
[15]. In addition, 19 autosomal recessive CVID families
were collected at the Department of Rheumatology and
Clinical Immunology in Freiburg, Germany, from 2001 to
2005. The families were considered as having possible
recessive inheritance when two or more siblings in one
generation were affected by CVID and their parents and
children had normal immunoglobulin levels. Alterna-
tively, ten families were considered as recessive because of
a known consanguinity in these families. Six families orig-
inated from Turkey, five from Germany, four from Italy,
two from the UK and one from Sweden. For the analysis
of TNFRSF17, encoding BCMA, fifty additional individu-
als with sporadic CVID followed in the Department of
Pediatrics, University of Brescia were included in this
study. Informed written consent was obtained from each
patient or parent guardians prior to participation under
the internal ethics review board-approved clinical study
protocol (ZERM, University Hospital Freiburg (#239/99).
Linkage analysis
Genetic linkage analysis was carried out by computing
LOD scores using a dominant model and imperfect pene-
trance using FASTLINK [35-37], as previously described
[11]. We also tried a recessive model in which the pene-
trance for heterozygotes is assumed to be the same (0.05)
as for individuals with no disease-associated alleles. For
each candidate gene, we tried to find close flanking mark-
ers from the marker set chosen for the previous studies
[9,10]. The relevant markers near each gene are shown in
Table 1. We tried to find families with positive scores at all
flanking markers, but sometimes had to settle for families
with positive scores at one or some flanking marker(s)
and 0 scores (either due to no genotypes or an uninforma-
tive marker) at some flanking marker(s). With the excep-
tions of cv32 and cv74, all the families are small and have
maximum achievable scores under 1.0. Thus, the positive
Table 3: Description and analysis of SNPs found in CVID patients
Gene SNP SIFT[30] Polyphen[31] CVID Genotypes Healthy donors Genotypes Additional studies
BCMA S81N tolerated benign T/T T/C C/C T/T T/C C/C n.a.
rs373496 0 0,014 0,986 0* 0,050* 0,950*
synonymous (T159) n.a. n.a. T/T T/C C/C T/T T/C C/C no aberrant
rs2017662 0,071 0,029 0,900 0* 0,136* 0,864* splicing of mRNA
synonymous (T175) n.a. n.a. T/T T/C C/C T/T T/C C/C no aberrant
rs2071336 0,071 0,029 0,900 0* 0,117* 0,883* splicing of mRNA
K179Q not tolerated benign C/C C/A A/A C/C C/A A/A no segregation, normal 
expression
0 0,014 0,986 n.k. n.k. n.k.
APRIL G67R tolerated benign A/A A/G G/G A/A A/G G/G n.a.
rs11552708 0 0,190 0,810 0,033* 0,233* 0,733*
N96S tolerated benign G/G G/A A/A G/G G/A A/A n.a.
rs3803800 0,632 0,316 0,053 0,683* 0,183* 0,133*
IL10 3' UTR n.a. n.a. C/C C/T T/T C/C C/T T/T n.a.
rs3024496 0,210 0,368 0,421 0,293* 0,500* 0,207*
IL10RA synonymous (A153) n.a. n.a. A/A A/G G/G A/A A/G G/G n.a.
rs2256111 0,154 0,346 0,500 0,328* 0,448* 0,224*
I224V tolerated benign A/A A/G G/G A/A A/G G/G n.a.
rs17121493 0,846 0,154 0 0,917* 0,083* 0*
IL21 synonymous (C78) n.a. n.a. G/G G/A A/A G/G G/A A/A n.a.
rs4833837 0,200 0,360 0,440 0,174** 0,522** 0,304**
IL21R 5' UTR rs961914 n.a. n.a. T/T T/C C/C Allele T Allele C n.a.
0,042 0,167 0,792 0,140*** 0,860***
T46M tolerated benign T/T T/C C/C T/T T/C C/C n.a.
0 0,042 0,958 0 0,010 0,990
R275Q tolerated benign A/A A/G G/G A/A A/G G/G n.a.
0 0,042 0,958 0 0,050 0,950
The observed known and newly discovered SNPs are listed in the table. The table summarizes in silico analysis results by SIFT and Polyphen for 
missense mutations and the frequencies of SNPs in CVID patients versus healthy control populations. n.a., not applicable. n.k., not known. * 
HapMap CEU, ** PGA-EUROPEAN-PANEL, *** CEPHBMC Immunology 2008, 9:3 http://www.biomedcentral.com/1471-2172/9/3
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scores should be taken only as evidence that these families
are consistent with linkage and preferred over families
with negative LOD scores, but we make no claims of sta-
tistically significant linkage. Based on these criteria, the
families which were consistent with linkage for each indi-
vidual candidate gene were selected out of the previously
described cohort [9,10] (Table 1, Figure 1).
Sequencing of candidate genes
Candidate genes were evaluated by sequencing the coding
regions of the genes on genomic DNA including 20 bp of
the flanking intronic or untranslated regions. All primers
were sought with the aid of the Primer Select software (PE
Applied Biosystems, Foster City, CA, USA); sequences are
summarized in Table 2. Genomic DNA was amplified by
PCR and subsequently sequenced with the amplification
primers. After gel electrophoresis on an ABI Prism™ 377
DNA Sequencer, the data was analyzed by the DNA
Sequencing Analysis software, version 3.4 (PE Applied
Biosystems) and Sequencer™, version 3.4.1 (Gene Codes
Corporation, Ann Arbor, MI, USA).
Authors' contributions
US evaluated candidate genes and wrote the manuscript.
CN, JT, CW, QP, VL, TH, JJ, JB, LD performed sequencing
of candidate genes, evaluated primary data and partici-
pated in preparation of the manuscript. AM, AP, VM col-
lected and evaluated CVID families and provided DNA
samples for candidate gene analysis. AW, LH collected
and evaluated CVID families for linkage analysis and pro-
vided DNA from these families. AS evaluated genetic link-
age analysis data and selected families for analysis of
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